Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 796 results for "Shionogi"

Aurobindo Pharma in a legal tangle

Japanese drugmaker Shionogi has sued Indian company Aurobindo Pharma in an attempt to stop it from producing the generic version of their drug Doribax. Aurobindo had filed for an abbreviated new drug application last year seeking FDA's go-ahead to ... Financial Chronicle, 5 days ago

BRIEF-Shionogi to buy back up to 30 bln yen of own shares

TOKYO Dec 1 (Reuters) - Shionogi & Co Ltd : * Says to buy back up to 2.99 percent of own shares for as much as 30 billion yen Further
 Reuters UK1 month ago

EMA Backs Ospemifene (Senshio) for Vulvar and Vaginal Atrophy

Ospemifene ( Senshio , Shionogi Limited) was recommended by a European Medicines Agency (EMA) panel for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are unable to use local vaginal estrogen ...
 American Journal of Public Health2 months ago CHMP nods several drugs through  Pharmafocus2 months ago More November EMA/CHMP recommendations  Pharma Letter2 months ago News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014  European Medicines Agency2 months ago

Mylan reports availability of first generic Orapred ODT, with 180 days of marketing exclusivity

Pharmaceutical company Mylan The company said the product is the first generic version of Shionogi's Orapred ODT, which is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain ...
 BusinessWeek1 month ago Mylan launches generic anti-inflammatory drug  Individual.com1 month ago Mylan introduces generic Orapred ODT in US market  PharmaBiz1 month ago Mylan Launches Generic Orapred ODT  Monthly Prescribing Reference1 month ago

SHIONOGI : Data from Shionogi & Co. Ltd. Advance Knowledge in Solid Cancer (Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine...

Data from Shionogi & Co. Ltd. Advance Knowledge in Solid Cancer (Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours) By a News Reporter-Staff News Editor ...
 4 Traders2 days ago
Social Dashboard

New and Generic Drug Approvals: Ponstel

Drug Name(s) PONSTEL FDA Application No. (NDA) 015034 Active Ingredient(s) MEFENAMIC ACID Company SHIONOGI INC Original Approval or Tentative Approval Date March 28, 1967 Chemical Type ...
 U.S. Food and Drug Administration2 weeks ago UPDATE 1-FDA approves BioCryst's intravenous flu drug  CNBC1 month ago UPDATE 2-FDA approves BioCryst's intravenous flu drug  Reuters UK1 month ago FDA approves BioCryst's intravenous flu drug  Social Dashboard1 month ago

Shionogi & Co., Ltd.: R&I Affirms A+, Stable

Rating and Investment Information, Inc. (R&I) has announced the following: The royalty income from hyperlipidemia treatment "Crestor", which has grown to the world's third by sales, supports the overall earnings of Shionogi & Co., Ltd. In order to ...
 Noodls1 month ago
Global Information Inc

Emerging Markets Driving Anxiety Disorders Industry Growth Globally to 2019

/PRNewswire/ -- The Global Anxiety Disorders Market 2015-2019 research report, now available with, says that in addition to emerging markets' focus, the key vendors are trying to penetrate the market by organizing awareness ...
 Town Hall3 days ago Global Anxiety Disorders Market 2015-2019  companiesandmarkets.com2 days ago

Nikkei ends over 1% on ECB QE package

(Mumbai) - The Japanese equities index jumped close to one-month highs and closed higher cheering the newly-announced quantitative easing (QE) program by the ECB in the previous session. The benchmark Nikkei 225 index ended 1.05% higher at 17511.75 ...
 FXStreet.com2 days ago

Knight Therapeutics appoints Schutter to board

KNIGHT THERAPEUTICS INC. ANNOUNCES BOARD CHANGE Hillel Rosen has resigned as a director of Knight Therapeutics Inc. The company has appointed Ed Schutter to Knight's board of directors. "Hillel will continue to provide legal counsel to Knight and ...
 Stockwatch4 days ago Knight Therapeutics Inc. : Announces Board Change  4 Traders4 days ago KNIGHT THERAPEUTICS : Announces Board Change  4 Traders4 days ago Knight Therapeutics Announces Board Change  FirstWord Pharma4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less